A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Summary

The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.

Timeline

Start

2023-02-09

Primary completion

2025-11

Completion

2027-06

Drugs

Indications